Skip to main content
On Demand

Topics in Pulmonary Medicine

Total Credits: 2.0 including 2 AOA Category 1-A Credit(s)

Average Rating:
Not yet rated
State Associations:
OOA - Ohio
Timothy Barreiro, DO |  Robert Schilz, DO
Never expires.


Learning Objectives:

To survey important, new or emerging concepts and therapies in pulmonary medicine in the areas of:

  • Asthma
  • COPD
  • Lung Cancer
  • Pulmonary Embolism
  • Pulmonary Hypertension
  • Sleep Medicine
  • Spirometry
  • Vaccination

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Ohio Osteopathic Foundation (OOF) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.

Grievance Policy: The OOF strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to OOA Executive Director Heidi Weber, by calling the OOF Office at 614-299-2107 or by mail to OOF, PO Box 8130, Columbus OH 43201, or by email to



Timothy Barreiro, DO's Profile

Timothy Barreiro, DO Related Seminars and Products

As a Professor of Medicine, Timothy J. Barreiro has demonstrated determination for working and caring for the underserved and has a commitment and appreciation for diversity, education, and mentoring.  He has coached hundreds of residents going into leadership and fellowship positions. He is the Director of a multidisciplinary team that researches complex diseases of the pulmonary system.

He obtained his Doctorate of Osteopathy from Ohio University Heritage College of Osteopathic Medicine in Athens, OH. He went on to specialty training in pulmonary, critical care, and sleep at the University of Rochester School of Medicine & Dentistry, Strong Memorial Hospital, Rochester, NY.  It was early in his career path where he as entitled Health Disparities Scholar, National Center on Minority Health & Health Disparities, by the Department of Health & Human Services Public Health Service, National Institute of Health for his work on cultural complexities in decision-making attitudes and skills.

Dr. Barreiro has no disclosures. 

Robert Schilz, DO's Profile

Robert Schilz, DO Related Seminars and Products

Dr. Robert Schilz is director of the Pulmonary Vascular Disease Program at University Hospitals Cleveland Medical Center. He is also an Associate Professor at Case Western Reserve University School of Medicine.

Dr. Schilz earned Doctor of Osteopathic Medicine (DO) and Doctor of Philosophy (PhD) degrees from the Michigan State University Medical Scientist Training program. He then completed a Residency and Chief Residency at the Cleveland Clinic in Cleveland, Ohio. He also completed Pulmonary & Critical Care and Research fellowships at Yale University. Prior to joining University Hospitals, Dr. Schilz was on staff at the Cleveland Clinic in Pulmonary and Critical Care Medicine.

For over 25 years, Dr. Schilz has participated in clinical and basic research in the areas of advanced lung diseases and pulmonary hypertension, with numerous publications in the areas of pulmonary hypertension, lung transplantation and advanced lung disease.

Dr. Schilz serves or has served as an advisor or committee member for a number of state, national and international organizations, including the International Society for Heart Lung Transplantation, American College of Chest Physicians, Pulmonary Hypertension Association and the Ohio State Board of Hospitals. He is a past Associate Editor of Advances in Pulmonary Hypertension and reviewer for a number of international journals. He has been consistently named as “One of America’s Best Doctors” since 2005.

Potential Conflict of Interests:
• Research – Respira, United Therapeutics
• Speakers Bureau – Actelion J&J, Bayer, Liquidia, United Therapeutics
• Consultant – Actelion J&J, Acceleron, United Therapeutics